The next frontier of the life sciences

This is a bonus edition of PharmaVoice’s daily newsletter. Today, we’re looking at the trends transforming the life sciences sector. For other industry insights, sign up here to receive our newsletter in your inbox every morning.?

Innovation is the lifeblood of the life sciences sector. And as the pandemic fades away, new trends are taking hold that could transform drug development.

Later this year, for instance, the FDA could approve the first-ever CRISPR gene editing therapy, leading the way for a growing field of candidates that aim to not only treat, but cure a range of illnesses.?

Research into once-confounding disease areas like Alzheimer’s, ALS and weight loss is also heating up — with the outlook for treatments better than ever before.?

And on the digital front, AI adoption is expediting the drug discovery process while wearable devices are helping unlock the potential of truly decentralized trials.?

As we look toward the next frontiers of the industry, it’s the architects of these inventions who will steer the way, helping to streamline once-complicated processes.?

So how can companies navigate this rapidly evolving landscape? We’ll be unpacking the must-know strategies for staying future-focused while examining hot industry trends later this month at a two-day virtual event hosted in partnership with our sister publication BioPharma Dive. Take a look at our panels, which will bring together newsmaking leaders from across pharma and biotech and then register here.

In the meantime, catch up on our latest coverage of the hot-button issues facing the industry.?

Do humans have a place in pharma’s AI future?

From COTA’s large datasets and AI model assistants to a company guiding patients through cancer care, AI can help — but it’s a long way from human-free.

In the era of blockbuster obesity drugs, a personalized approach could boost outcomes

Ozempic and Wegovy have become household names for weight loss. But obesity is complex, and Phenomix Sciences is looking to bring a personalized medicine approach to the field.

New Alzheimer’s treatments are the tip of the iceberg in a long-stymied area of medicine

A smaller player in the Alzheimer’s space, Prothena is approaching the next phase of treatments, including prevention and clinical trial evolution.

What pharma companies are getting wrong about drug repositioning

Children’s Tumor Foundation president Annette Bakker is working to teach the industry the crucial difference between drug repurposing and drug repositioning.

This is just a sampling of PharmaVoice’s coverage. For more insights into the biggest trends and voices swaying the life sciences industry, be sure to check out our daily newsletter.